COMP <GO>
RYTM vs MRK // ENTERPRISE SCALE & MARKET CAP
Rhythm Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: RYTM 4
— MRK 10
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $92.57 (-0.54%) • MKT CAP: $6.41B
market-cap
$6.41B
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RYTM | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.70% | 74.80% | +14.90 | RYTM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.60% | 20.70% | -50.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.82% | 3.42% | -5.24 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -0.10% | 28.10% | -28.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 45.80% | 1.30% | +44.50 | RYTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 5.19 | +9.14 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.3 | 56.9 | -6.61 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.92 | +0.04 | RYTM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 18.4x | +14.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $6.41B | $361.02B | -$354.61B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RYTM REV | MRK REV | RYTM GROSS % | MRK GROSS % | RYTM FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | $65.01B | 89.7% | 74.8% | -$116.6M | $12.36B |
| FY 2024 | $130.1M | $64.17B | 89.7% | 76.3% | -$113.9M | $18.10B |
| FY 2023 | $77.4M | $60.12B | 44.0% | 44.0% | -$139.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
MRK // BETA 0.92